



## PET/CT Referral Form

NPI#: 1538113113 | TAX ID#: 043-59-3126

### PATIENT INFORMATION

<input type="checkbox"/> Patient Name	<input type="checkbox"/> Date of Birth	<input type="checkbox"/> Height	<input type="checkbox"/> Weight
<input type="checkbox"/> Patient Address	<input type="checkbox"/> Patient Telephone #	<input type="checkbox"/> Patient Mobile #	
<input type="checkbox"/> Referring Provider	<input type="checkbox"/> Provider Telephone #	<input type="checkbox"/> Provider Fax#	

### SIGNS AND SYMPTOMS (REQUIRED)

Histologically Proven     Suspected

**Type of cancer** \_\_\_\_\_

**Please check Radiopharmaceutical**

FDG     Amyvid     Axumin     Pylarify  
 Illucix     Netspot     Detectnet

**CPT Codes** \_\_\_\_\_  
If provided a specific CPT code, please provide.

### INSURANCE INFORMATION

Primary Insurance                       Subscribers Insurance ID #

Secondary Insurance                      Insurance Prior Authorization #

### CMS/APPROPRIATE USE CRITERIA (FOR MEDICARE PART B PATIENTS ONLY)

**NPI#** \_\_\_\_\_    **Name of CDSM Consulted (software used)** \_\_\_\_\_    **Determination Result (check one):**  
 1) Adheres to     2) Does Not Adhere to     3) Not Applicable

### (Check ONE and fill out corresponding section completely)

#### Initial Treatment Strategy

**Diagnosis:** Abnormal finding of \_\_\_\_\_  
Based on \_\_\_\_\_

**Check one**

To determine whether the patient is a candidate for an invasive diagnosis or therapeutic procedure;

To determine the optimal anatomic location for an invasive procedure; or

To determine the anatomic extent of the tumor when the treatment recommendations depend on the extent,

**Initial Staging:** of confirmed newly diagnosed cancer

**Check one**

To determine whether the patient is a candidate for an invasive diagnosis or therapeutic procedure;

To determine the optimal anatomic location for an invasive procedure; or

To determine the anatomic extent of the tumor when the treatment recommendations depend on the extent.

**Other** (e.g., Alzheimer's Disease). Please list reason for scan here:  
\_\_\_\_\_

#### Subsequent Treatment Strategy

**Restaging:** (after the completion of treatment)

**Check one**

Status post the completion of treatment for the purpose of detecting residual disease  
Last date of treatment: \_\_\_\_\_  
Type of treatment: \_\_\_\_\_

Detecting suspected recurrence, or metastasis of previously treated cancer:  
Site of suspected recurrence / metastasis: \_\_\_\_\_  
Based on: \_\_\_\_\_

Determine the extent of a known recurrence.  
Confirmed by: \_\_\_\_\_

PET/CT is being used to potentially replace one or more imaging studies that (1) is being utilized to determine extent of known recurrence of (2) provided insufficient information for the clinical management of the patient.

**Monitoring Tumor Response:** During Treatment

**Check one**

Chemotherapy     Radiotherapy     Other (specify): \_\_\_\_\_

### PRESCREENING QUESTIONNAIRE

#### Prior Studies/Treatment

Pregnant: <input type="checkbox"/> Y <input type="checkbox"/> N	Previous: <input type="checkbox"/> CT <input type="checkbox"/> MRI <input type="checkbox"/> PET/CT	Where: _____	When: _____
Diabetes: <input type="checkbox"/> Y <input type="checkbox"/> N	Pathology: <input type="checkbox"/> Y <input type="checkbox"/> N	Where: _____	When: _____
	Radiation Therapy: <input type="checkbox"/> Y <input type="checkbox"/> N	Provider: _____	When: _____
	Chemotherapy: <input type="checkbox"/> Y <input type="checkbox"/> N	Provider: _____	When: _____

**Authorized Treating Provider's Signature:** (Stamps Not Accepted) \_\_\_\_\_     **NPI #** \_\_\_\_\_     **Date** \_\_\_\_\_



Please FAX this form (and recent office notes, radiology reports and pathology reports) to our Scheduling Department after patient's examination has been scheduled.